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Introduction: Chronic obstructive pulmonary disease (COPD) is an 
independent risk factor for lung cancer development, but the mecha-
nism is not fully understood. Muscarinic receptor 3 (M3R) has been 
found to be involved in the progression of small-cell lung cancer 
and the pathological process of COPD. We hypothesized that M3R 
may contribute to lung cancer development, especially in patients 
with COPD.
Methods: The correlation between M3R expression and clinical 
features of non–small-cell lung cancer (NSCLC) was evaluated in 
148 paraffin-embedded archived NSCLC specimens with the use of 
immunohistochemistry. M3R agonist and siRNA treatments were 
used to study the role of M3R in NSCLC cell lines. Western blotting 
and zymography were used to examine the impact of M3R on the 
PI3K/Akt/matrix metalloproteinase 9 signaling pathway.
Results: The expression of M3R in NSCLC was significantly 
increased and correlated with tumor metastasis and poor survival of 
NSCLC patients. NSCLC patients with COPD showed higher expres-
sion of M3R than those without COPD (p = 0.0014). Moreover, M3R 
expression was inversely related to percent forced expiratory volume 
in 1 second (r = 0.7017, p < 0.0001) and forced expiratory volume 
in 1 second /forced vital capacity (r = 0.5057, p < 0.0001), but posi-
tively related to smoking history. Down-regulation of M3R resulted 
in the inhibition of migration and invasion ability of NSCLC cell 
lines A549 and L78. Furthermore, M3R enhanced the expression and 
activity of matrix metalloproteinase 9 through PI3K/Akt, which pro-
moted the migration and invasion of NSCLC cell lines.
Conclusion: Our results suggest that overexpression of M3R in 
NSCLC promotes the progression of NSCLC, which could contribute 
to lung cancer development in COPD patients. M3R could be another 
pharmacological target in lung cancer, especially in COPD patients.
Key Words: Non–small-cell lung cancer, Chronic obstructive pul-
monary disease, Muscarinic receptor 3, Invasion, Metastasis.
(J Thorac Oncol. 2014;9: 170–178)
Lung cancer is the leading cause of cancer-related death in the world and approximately 80% to 85% of lung cancers 
are non–small-cell lung cancer (NSCLC).1 The prevalence and 
mortality of lung cancer have been increasing dramatically 
in recent years, not only in developing countries like China, 
but also in developed countries of Europe.2 Lung cancer will 
overtake breast cancer and become the leading cause of death 
in women.2 The leading cause of death from lung cancer is 
metastasis. Often, metastasis already occurs even before the 
diagnosis of lung cancer is made, leading to recurrence and 
treatment failure in lung cancer patients.
Chronic obstructive pulmonary disease (COPD) is 
characterized by progressive obstruction of the airway, which 
is not fully reversible after treatment with bronchodilators.3 
COPD patients are at great risk for developing lung cancer.4 
Multiple studies have shown that individuals with emphysema 
and airway obstruction have an increased risk for the develop-
ment of lung cancer and a worse prognosis.5 And lung can-
cer screening is necessary in COPD patients.6 However, the 
mechanism of COPD in promoting lung cancer development 
is not well understood.
Muscarinic receptor 3 (M3R) is one of the five musca-
rinic receptors (M1R-M5R)7 which plays an important role in 
many pathological processes of lung disease, including COPD. 
And the use of drugs targeting M3R has become one of the 
basic therapies for COPD.8–11 Recent studies have shown that 
M3R is a major player in many kinds of cancer, like colon 
cancer, gastric cancer, breast cancer, and lung cancer.12–15 
It has been shown that acetylcholine (Ach) promotes prolif-
eration and cell migration of small-cell lung cancer (SCLC) 
through M3R.16,17 Our previous study also confirmed the role 
of M3R in enabling cell adherence to the extracellular matrix.18 
However, the role of M3R in NSCLC progression has not been 
fully investigated. We hypothesized that overexpression and 
activation of M3R may contribute to lung cancer development 
and metastasis in patients with COPD. To test this hypothesis, 
we examined the expression of M3R in NSCLC tissues and 
explored the relationship between the intensity and clinical–
pathological features such as metastasis status and the 5-year 
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survival rate of NSCLC patients. We also used an M3R agonist 
and siRNA to study the influence of M3R on the migration 
and invasion behavior of NSCLC cell lines. Finally, we veri-
fied which signal pathway could be responsible in this process.
MATERIALS AND METHODS
Patient Information and Tissue Specimens
Paraffin-embedded archived NSCLC samples were 
obtained from 148 patients diagnosed with NSCLC between 
January 2000 and December 2007 in the Department of 
Pathology at the First Affiliated Hospital of Sun Yat-sen 
University. Of these, 60 cases were diagnosed with COPD and 
88 cases were not diagnosed with COPD. The histological char-
acterization and clinical–pathological staging of the samples was 
determined according to World Health Organization criteria19 
and the current International Union Against Cancer tumor-node-
metastasis classification20 or International Association for the 
Study of Lung Cancer  tumor-node-metastasis classification. The 
diagnosis of COPD was made according to Global Initiative for 
Obstructive Lung Disease.21 Detailed clinical information for all 
patients is summarized in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A514).
Cell Lines and Cell Culture
Human lung adenocarcinoma cell lines A549, PC9, SPC-
A1, and GLC82, human squamous lung cancer cell line L78, 
and human lung fibroblast (HLF) cell line were used in this 
study. Among them, A549, PC9, and HLF were obtained from 
Cell Bank, Chinese Academy of Sciences (Shanghai, China) 
and kept in our laboratory. SPC-A1, GLC82, and L78 were 
generously provided by Prof. Liantang Wang from Department 
of Pathology in the First Affiliated Hospital of Sun Yat-Sen 
University. Cells were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Gibco, BRL, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Gibco, BRL) at 
37°C in a humidified incubator with 95% air and 5% CO
2
.
Quantitative Real-Time 
Polymerase Chain Reaction
Total RNA was isolated from the cells using Trizol 
reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. Quantitative real-time polymerase chain 
reaction was carried out using the FastStart Universal SYBR 
Green Master(ROX, Roche, Toronto, Ontario, Canada) on 
the ABI StepOne quantitative real-time polymerase chain 
reaction detection system. Beta-actin was used as refer-
ence gene. The sequences of the primer pairs were as fol-
lows: M3R, 5'-GCCAAACGAACAACAAAGAGAG-3' 
(F) and 5 '-CCAACAAAGTATTGCCAG AACA-3' (R); 
β-actin, 5'-CGCCAGCTCACCATGGATGATGAT-3' (F) and 
5'-TCTCTTGCTCTGGGCCTCGTCG-3' (R). Each sample was 
tested in triplicate and the mean expression level was calculated.
Western Blot Analysis
Total protein was extracted from cells with a lysis buffer. 
Protein concentration was measured using the BCA Protein 
Assay kit (CWBiotech, Beijing, China). Equal amounts of 
protein were separated by sodium dodecyl sulfate (SDS) poly-
acrylamide (10% gel). After electrophoretic transfer to a poly-
vinylidene difluoride membrane, nonspecific binding sites were 
blocked with 5% nonfat milk in Tris-buffered saline Tween-20 
(TBST) (0.1% Tween 20) followed by incubation with primary 
antibodies overnight at 4°C. After three rinses with TBST, anti-
rabbit HRP secondary antibody (1:5000) or antimouse horse-
radish peroxidase (HRP) secondary antibody (1:5000) was 
added. Protein bands were detected using enhanced chemilu-
minescence (Millipore, Billerica, MA).
Immunohistochemistry
Immunohistochemistry (IHC) studies were performed 
using a standard streptavidin-biotin-peroxidase complex 
method (EnVision™ Detection Systems, Dako, Copenhagen, 
Denmark). Slides were incubated with polyclonal rabbit anti-
human M3R (1:300, Santa Cruz, Dallas, TX) overnight at 
4°C. A semiquantitative scoring criterion for IHC of M3R 
was used, in which both staining intensity and positive areas 
were recorded. A staining index (values 0–12), obtained as 
the intensity of M3R positive staining (negative = 0, weak = 1, 
moderate = 2, or strong = 3 scores) and the proportion 
of  immune-staining positive cells of interest (< 25% = 1, 
25%–50% = 2, > 50%– < 75% = 3, ≥75% = 4 scores) were cal-
culated. Two independent pathologists (RW and MZ) blinded 
to clinical–pathological information performed the scorings. 
Cutoff values to define high and low expression of M3R were 
chosen according to a measure of heterogeneity by using log-
rank test statistics with respect to overall survival. An optimal 
cutoff value was identified. A score of more than 6 was used to 
define tumors with high expression and a score of 6 or lower 
defined tumors with low expression of M3R.
Cell Proliferation Assay
A549 and PC9 cells were plated on 96-well plates 
(Corning, NY) and allowed to attach overnight. After 
24 hours, 48 hours, and 72 hours, 20 μl of 5 mg/ml methyl 
thiazole tetrazolium (MTT) (Sigma, St. Louis, MO) solution 
was added to each well and incubated for 4 hours at 37°C. 
After the media was removed, 200 μl of DMSO (Sigma) was 
added and absorbance values at 490 nm were recorded using a 
microculture plate reader.
Wound-Healing Assay
A549 and L78 cells were grown to confluence in cell 
culture dishes. A wound was inflicted on the monolayer by 
using a pipette tip. Cells were then serum starved and allowed 
to migrate for 24 hours.
Cell Migration and Invasion Assays
Cell migration assays were performed using a 24-well 
transwell chamber with an 8.0 μm pore polycarbonate mem-
brane insert (Corning). For the invasion assay, the inserts were 
coated with 40 μl Matrigel (1:8 dilution; BD Bioscience, 
Bedford, MA) Cells (1 × 105) in 0.5 ml of serum-free media 
were placed in the upper compartment. The lower chamber 
was filled with 600 μl of media supplemented with 10% 
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fetal bovine serum. After incubation for 24 hours, the cells 
on the upper surface of the membrane were removed and the 
migrated cells on the lower surface were fixed with methanol 
and stained with crystal violet. Numbers of invaded cells were 
counted in 10 randomly selected high-power fields under a 
microscope. These experiments were performed in triplicate.
siRNA treatment
Cells were seeded in a 6-well plate 24 hours before 
transfection. The siRNAs were transfected at a concentration 
of 50 nmol/liter each with RNAiMax (Invitrogen) according 
to the manufacturer’s instructions. After transfection, mRNA 
and protein levels were assessed 24 hours and 48 hours later, 
respectively. The target sequences of M3R siRNAs are as fol-
lows: 5'- CGAGCCAAACGAACAACAA -3' (si 1) and 5'- 
CCTGGTAATTGTGTCATTT-3' (si 2).
Zymography
Cells were cultured in fresh RPMI 1640 medium for 
another 24 hours after treatment. Culture media was then col-
lected and centrifuged, and the supernatant was preserved. 
Before measuring the protein concentration using the BCA 
kit, the culture medium was concentrated using ultrafiltration 
(Millpore, Billerica, MA). Protein (20 ug) was loaded and 
separated using a 10% SDS polyacrylamide gel containing 
1% gelatin at 27 mA/gel and 4°C. The gel was then washed, 
incubated, stained, and destained following the instructions of 
the gelatin zymography kit (Applygen, Beijing, China).
Statistical Assay
Data are expressed as mean ± standard deviation from 
three independent experiments. Comparisons among groups 
were performed using Student’s t test or one-way analysis of 
variance. The χ2 test and Spearman analysis were used to ana-
lyze the relationship between M3R expression and clinical–
pathological characteristics. Spearman analysis was used to 
examine the relationship between M3R expression and lung 
function. Kaplan–Meier method was performed to plot sur-
vival curves whereas the log-rank test was used to compare 
survival curves. Univariate and multivariate Cox regression 
analyses test were also performed to identify possible risk fac-
tors. A value of p less than 0.05 was considered statistically 
significant. Statistical tests were performed using SPSS 13.0.
RESULTS
Increased Expression of M3R in 
NSCLC Cell Lines and Tissues
Western blotting was used to determine M3R pro-
tein expression both in human NSCLC cell lines, including 
A549, PC9, SPC-A1, GLC82, and L78, and a human lung 
fibroblast cell line HLF. All NSCLC cell lines demonstrated 
notably higher levels of M3R expression compared with HLF 
(Fig. 1A). Furthermore, comparative analysis of M3R expres-
sion was conducted on 10 pairs of matched NSCLC tissue and 
adjacent noncancerous tissue. The expression of M3R protein 
in eight NSCLC samples was much higher than in the paired 
adjacent noncancerous tissue (Fig. 1B). The specificity of the 
M3R antibody used in the study is shown in Supplementary 
Figure 1 (Supplemental Digital Content 2, http://links.lww.
com/JTO/A515).
Association between Increased Expression 
of M3R and Progression of NSCLC
To further examine whether increased expression of 
M3R was related to the progression of NSCLC, 148 cases of 
archived paraffin-embedded samples were assayed using IHC. 
The mean age of the 148 NSCLC patients was 64.4 years 
(range, 24–86 years), and the follow-up period was from 0.7 
to 90 months, with a median of 21.3 months. A total of 114 
deaths were reported during the follow-up period.
The results of IHC staining are summarized in 
Supplementary Table 2 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A514). M3R was highly expressed 
in 85 of 148 human NSCLC samples (57.4%), with no sig-
nificance observed among the three different subtype groups 
(p = 0.081), namely squamous cell carcinoma, adenocar-
cinoma, and other subtypes such as large cell carcinoma. 
Moreover, the expression level of M3R correlated with the pro-
gression of NSCLC. Statistical analyses showed no relation-
ship between patient age or sex and M3R expression. However, 
M3R expression strongly correlated with clinical stage 
(p = 0.003), N classification (p = 0.009), and M classifica-
tion (p = 0.001) of NSCLC patients. Spearman analyses also 
revealed a correlation between M3R expression level and 
clinical stage (p < 0.001), N classification (p < 0.001), and M 
classification (p < 0.001).
FIGURE 1.  M3R is overexpressed in 
both NSCLC cell lines and tissues. A 
Western blot analysis of M3R expres-
sion in NSCLC cell lines (GLC82, PC9, 
SPC-A1, A549, and L78) and HLF. B, 
Western blot analysis of M3R protein 
level in 10 pairs of tissues (T: tumor, 
N: adjacent noncancerous lung tis-
sue). β-actin was used as a loading 
control. M3R, muscarinic receptor 3; 
NSCLC, non–small-cell lung cancer; 
and HLF.
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Association between M3R Expression 
and Prognosis for NSCLC Patients
Statistical analysis revealed an inverse correlation 
between M3R expression level and the NSCLC patient cumula-
tive 5-year survival rate. The cumulative 5-year survival rate of 
patients with low M3R expression was 39.3% (95% confidence 
interval [CI]: 27.15%–51.45%), whereas the 5-year survival of 
those patients with high M3R expression was 12.9% (95% CI: 
5.84%–19.96%). We next explored the role of M3R in predicting 
the prognosis of NSCLC patients with or without COPD. In the 
COPD group, patients with a high level of M3R had a survival 
rate of 9.4% (95% CI: 4.30%–14.50%), which was significantly 
lower than the survival rate of those patients with a low level 
of M3R (38.5%, 95% CI: 27.72%–38.39%). In patients with-
out COPD, a high level of M3R also predicted a poorer 5-year 
survival rate (16.5%, 95% CI: 10.03%–22.97%) than did a low 
level of M3R (39.9%, 95% CI: 30.69%–49.11%; Fig. 2B).
M3R expression, clinical stage, TMN classification, age, 
sex, and lung function status (with and without COPD) were 
analyzed by using univariable and multivariable Cox regression 
analyses. Univariable analyses revealed that clinical stage, M3R 
expression, TMN classification, and lung function status were 
significant predictors of NSCLC. Multivariable analysis showed 
that clinical stage, M3R expression, and lung function status 
were independent predictors of NSCLC prognosis (Table 1).
Expression Level of M3R is Closely Related to 
Smoking History and Airway Obstruction Status
NSCLC patients with COPD had a higher level of 
M3R expression (Fig. 3A). This prompted us to investi-
gate the relationship between M3R expression and lung 
function. On the basis of a lung function test, 60 of 148 
NSCLC patients were diagnosed with COPD, with an aver-
age precent forced expiratory volume in 1 second (%FEV1; 
of the predicted value) of 61.7 ± 19.8%, and an aver-
age FEV1/forced vital capacity (FVC) of 53.6 ± 11.9%. 
Correlation analysis showed that the M3R expression level 
was conversely related to %FEV1 (r = 0.7017, p < 0.0001) 
and FEV1/FVC (r = 0.5057, p < 0.0001; Fig. 3B, C). 
We next explored the relationship between M3R expression 
and smoking history. M3R expression positively correlated 
with smoking history (r = 0.3169, p = 0.0014; Fig. 3D, E).
Role of M3R in the Growth of NSCLC Cell Lines
In light of a previous study showing that M3R pro-
motes cell growth in SCLC, we first analyzed M3R-induced 
cell growth in A549 and L78 cells. A549 and L78 were treated 
with M3R siRNA. The proliferation rate was determined by 
the MTT assay. Little reduction was observed in the pro-
liferation rate of A549 and L78 cells after siRNA treatment 
(p < 0.01; Fig 4B).
FIGURE 2.  Overexpression of M3R correlates with poor prognosis and metastasis in NSCLC patients. A, Representative immu-
nohistochemistry pictures of M3R expression in different NSCLC subtypes and normal lung tissues. B, Survival curves of NSCLC 
patients with high or low M3R expression (n = 148, p < 0.0001; left panel). Differences within subgroups of NSCLC with COPD 
(n = 60, p = 0.0003; middle panel) and NSCLC without COPD (n = 88, p = 0.0222; right panel). M3R, muscarinic receptor; 3 
NSCLC, non–small-cell lung cancer; COPD, chronic obstructive pulmonary disease.
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Role of M3R in Cell Invasion and 
Migration of NSCLC Cell Lines
Next, we investigated the role of M3R in the invasion 
and migration abilities of NSCLC cell lines. Activation of 
M3R with Ach significantly increased cell invasion into 
 Matrigel-coated transwell membranes (Supplementary 
Figure 2B, Supplemental Digital Content 3, http://links.
lww.com/JTO/A516), whereas down-regulation of M3R 
with siRNA resulted in reduced cell invasion (p < 0.01; Fig. 
4D). Similar results were also observed in wound-healing 
assays, where M3R agonist promoted cell migration in a 
scratch assay on monolayer-cultured cells (Supplementary 
Figure 2A, Supplemental Digital Content 3, http://links.
lww.com/JTO/A516; Fig. 4C). Taken together, these results 
suggest that M3R induces cell invasion and migration of 
NSCLC cell lines.
M3R Promotes Invasion and Migration through 
PI3K/Akt/Matrix Metalloproteinase 9
To further investigate the molecular mechanism by 
which M3R promotes invasion and migration, levels of 
 metastasis-related genes matrix metalloproteinase (MMP9) and 
E-cadherin were examined. Using zymography and Western 
blot, we demonstrated that activation of M3R resulted in the 
up-regulation of MMP9 expression and activity, and down-
regulation of E-cadherin (Fig.5C, D; Supplementary Figure 2C, 
D, Supplemental Digital Content 3, http://links.lww.com/JTO/
A516), whereas down-regulation of M3R attenuated the expres-
sion and activity of MMP9 and up-regulated E-cadherin (Fig. 
5A, B). Because Akt is an important factor in the metastatic pro-
cess for regulating MMP proteins and epithelial-mesenchymal 
(EMT)-related genes like E-cadherin, we investigated the rela-
tionship between M3R and Akt. Activation of M3R increased 
the level of p-Akt, whereas down-regulation of M3R decreased 
TABLE 1.  Univariate and Multivariate Analysis of Different Prognostic Parameters in Patients with Lung Cancer by Cox 
Regression Analysis (Forward Conditional)
Univariate Analysis Multivariate Analysis
Assigned 
Score p SE HR 95%CI p SE HR 95%CI
T classification 0.002 0.094 1.342 1.116–1.614
  I 1
  II 2
  III 3
  IV 4
N classification <0.001 0.076 1.539 1.325–1.787
  0 0
  1 1
  2 2
  3 3
M classification <0.001 0.233 3.947 2.498–6.234
  0 0
  1 1
TMN stage <0.001 0.100 1.880 1.547–2.285 <0.001 0.101 1.756 1.441–2.139
  I 1
  II 2
  III 3
  IV 4
M3R expression <0.001 0.199 2.398 1.623–3.545 0.001 0.206 1.987 1.327–2.974
  Low 0
  High 1
Lung function <0.001 0.192 2.194 1.506–3.198 0.002 0.196 1.839 1.253–2.698
  With COPD
  Without COPD
Age, yrs 0.156 0.209 1.345 0.893–2.026
  ≤60 0
  >60 1
Sex 0.285 0.238 1.289 0.809–2.055
  Female 0
  Male 1
SE, standard error; HR, hazard ratio; CI, confidence interval; M3R, muscarinic receptor; 3 TNM, tumor-node-metastasis; COPD, chronic obstructive pulmonary disease.
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p-Akt. Using the specific PI3K/Akt inhibitor, LY294002 (CST, 
Danvers, MA), we found that Ach-promoted invasion and migra-
tion was abolished and the activity and expression of MMP9 
levels decreased, whereas E-cadherin expression was slightly 
increased (Fig.5C, D). Furthermore, we used wound-healing 
and transwell assays to explore the effect of M3R activation and 
Akt inhibition via LY294002 on migration and invasion of A540 
and L78 cells. Migration and invasion, which were promoted 
by an Ach concentration of 10−4M, was abolished by LY294002 
(Fig.5E, F). These results demonstrate that M3R promotes inva-
sion and migration through the PI3K/Akt pathway.
DISCUSSION
This study describes the role of M3R in the progression of 
NSCLC, especially in the context of COPD. To our knowledge, this 
is the first study to demonstrate that M3R promotes migration and 
invasion of NSCLC, and that high expression of M3R is an indica-
tor of poor prognosis in NSCLC. Moreover, the expression level of 
M3R is significantly higher in NSCLC patients with COPD com-
pared with those in patients without COPD. Furthermore, the M3R 
expression level correlates inversely with %FEV1 and FEV1/
FVC, two important indices for evaluating the severity of COPD. 
Further, we investigated the molecular mechanism through which 
M3R mediates migration and invasion of NSCLC.
M3R, a G protein–coupled receptor, belongs to the family 
of muscarinic receptors (M1R–M5R).7 M3R is involved in the 
pathological process of COPD, including airway constriction,9 
sputum production,10 and macrophage infiltration.22 Inhaled 
M3R antagonists like tiotropium, have become the cornerstone 
in the treatment of COPD.3 Recently, M3R was found to be 
involved in the development of cancer. Previous work from our 
group and others has suggested that M3R promotes cell pro-
liferation and migration of SCLC cell lines, and that such pro-
motion can be inhibited by M3R antagonists.16,18 However, the 
role of M3R in the progression of NSCLC remains unclear. In 
this study, we address this gap in knowledge, and demonstrate 
that M3R promotes migration and invasion, but not prolifera-
tion of NSCLC. NSCLC cell lines treated with an M3R agonist 
demonstrate more aggressive behavior, however, down-regula-
tion of M3R does not significantly inhibit cell proliferation of 
NSCLC cell lines. These results were further confirmed by the 
correlation analysis between M3R expression level and NSCLC 
progression in 148 patients. The expression level of M3R cor-
relates with the metastasis status of NSCLC patients, but not 
with the tumor size. Even though M3R promotes progression 
of both SCLC and NSCLC, the mechanism of the different 
roles of M3R in cell growth among SCLC and NSCLC is still 
unclear. One possible explanation is that different histopatho-
logical subtypes of lung cancer arise from different cells of 
origin,23 and M3R may function differently among these cells. 
Nevertheless, the real situation in the patients with lung cancer 
may be different. Further research is needed to clarify the dif-
ferences between the roles of M3R in SCLC and NSCLC and 
we look forward to the results of clinical trials to test the use of 
M3R antagonists in COPD patients with lung cancer.
FIGURE 3.  Expression of M3R in NSCLC is associated with airway obstruction and smoking. A, Differences in M3R expression 
in NSCLC tissues between patients with and without COPD. B, Inverse correlation between M3R expression and FEV1/FVC  
(r = 0.5057, p < 0.0001). C, Inverse correlation between M3R expression and %FEV1 (r = 0.7017, p < 0.0001). D, M3R expression 
levels in NSCLC patients with and without a smoking history. E, Correlation between M3R expression and smoking (pack-years) 
(r = 0.3169, p = 0.0014). M3R, muscarinic receptor 3; NSCLC, non–small-cell lung cancer; FEV1, forced expiratory volume in 1 
second; FVC, forced vital capacity; COPD, chronic obstructive pulmonary disease.
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COPD is a risk factor and an indicator of worse progno-
sis of lung cancer. Patients with COPD have a 10-fold higher 
risk of developing lung cancer.4 Further, lung cancer patients 
with COPD have a significantly shorter survival time compared 
with those without COPD.5 This group of patients tends to have 
more rapid cancer progression. The underlying mechanism may 
FIGURE 4.  M3R promotes proliferation, migration, and invasion of non–small-cell lung cancer cell lines. A, Knockdown efficiency 
of M3R siRNA in A549 and L78 cells. B, Growth curves of L78 and A549 after M3R siRNA treatment. A small reduction of absorbance 
was observed after siRNA treatment (p < 0.01). C, Wound-healing assay to analyze cell migration after M3R siRNA treatment. D, 
Migration and invasion assay using a transwell system (representative images of migration chambers; average counts from 5 ran-
dom microscopic fields). M3R siRNA inhibited the migration and invasion ability of L78 and A549. M3R, muscarinic receptor 3.
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include chronic inflammation, oxidative stress, and genetic 
predisposition.24 However, none of these have been explored 
in depth. A recent study has suggested that hypoxia might pro-
mote tumor growth, and, thus, predispose COPD patients to 
lung cancer development.25 In our study, we found that lung 
cancer patients with COPD have a shorter survival time than 
those without COPD. The 5-year survival rate of lung cancer 
patients with COPD is only 11.7% (95% CI: 3.66%–19.7%), 
whereas the survival rate of those without COPD is 32.7% (95% 
CI: 22.9%–42.5%). Also, lung cancer patients with COPD have 
a higher expression level of M3R, which promotes migration 
and invasion of NSCLC. Thus, M3R could be involved in the 
development of lung cancer in patients with COPD. However, 
why M3R is highly expressed in NSCLC patients with COPD 
is still unclear. Recent studies suggested that smoking and 
inflammatory factors could be responsible. It has been reported 
that cigarette smoke extract increases the expression of M3R 
in 16HBE cell line, on both mRNA and protein levels.26 Tumor 
necrosis factor-α, an inflammatory factor elevated in COPD 
patients,27 was found to enhance the expression of M3R.28 
FIGURE 5.  M3R promotes the migration and invasion of non–small-cell lung cancer cell lines through the PI3K/Akt/MMP9 
pathway. A, Zymography of MMP9 in conditioned medium of cells treated with M3R siRNA. B and D, Western bot assay of p-Akt, 
Akt, E-cadherin, and MMP9 in indicated cells. B, Knockdown of M3R results in the reduced expression of p-Akt and MMP9, but 
elevated expression of E-cadherin. D, Activation of M3R by Ach induces expression of MMP9 and p-Akt, but reduces expression of 
E-cadherin. PI3K inhibitor abolishes the effect of Ach. C, Zymography of MMP9 using conditioned medium from cells treated with 
Ach and LY294002. E, Wound-healing assay for cells migration ability after Ach and LY294002 treatment. A concentration of 10−4M 
Ach promotes migration, but migration is abolished by LY294002. F, Migration and invasion assay using a transwell system (repre-
sentative images of migration chambers; average counts from 5 random microscopic fields). Cells were treated with 10-4M Ach with 
and without 20μM LY294002, respectively. A concentration of 10-4M Ach promotes migration while LY294002 treatment inhibits it. 
M3R, muscarinic receptor 3, Ach, acetylcholine; MMP9, matrix metalloproteinase 9; NC, negative control; pAKT, phosphor-AKT. 
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In our study, we found that M3R expression correlates with 
severity of airway obstruction and smoking. Chronic irritants, 
such as cigarette smoke, are pathologic factors of COPD, 
which causes chronic inflammation.3 Therefore, one possible 
explanation is that smoking causes M3R overexpression and 
inflammation in COPD patients, both of which induce airway 
obstruction. Because inhaled M3R antagonist has been widely 
used in COPD, M3R could be another therapeutic target for the 
prevention and treatment of lung cancer.
M3R has been found to mediate different signal path-
ways in different kinds of cancer.12 In SCLC cell lines, M3R 
regulates cell proliferation via the mitogen-activated protein 
kinase (MAPK) pathway.16 M3R also regulates the activity 
of E-cadherin and integrins, key factors in cell adhesion and 
migration of SCLC cell lines.29 In our study, we first examined 
whether M3R regulates  metastasis-related genes like MMP9 
and E-cadherin. Knockdown of M3R using siRNA resulted in a 
notable decrease of MMP9 and an increase of E-cadherin. This 
result was further verified by M3R agonist treatment. Next, we 
explored how M3R regulates these metastasis-related genes. 
The PI3K/Akt pathway, which has been reported to regulate 
the transcription of MMPs and EMT-related genes,30,31 was 
studied. Knockdown of M3R using siRNA leads to a decrease 
of p-Akt, without affecting total Akt. This suggests that M3R 
promotes invasion and migration of NSCLC through Akt.
In conclusion, our study shows that M3R induces inva-
sion and migration of NSCLC through Akt. M3R expression 
is higher in NSCLC with COPD. This implies that M3R could 
take part in the development of lung cancer in patients with 
COPD. Thus M3R antagonists could be useful in the treatment 
and prevention of lung cancer in COPD patients.
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